» Articles » PMID: 8606510

Steroid Therapy Can Modulate Gut Barrier Function, Host Defense, and Survival in Thermally Injured Mice

Overview
Journal J Surg Res
Specialty General Surgery
Date 1996 Apr 1
PMID 8606510
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Prednisone may be immunosuppressive and dehydroepiandrosterone may stimulate the immune response, but their effect on gut-origin sepsis caused by bacterial translocation has not been studied. Balb/c mice were treated orally with prednisone (1 or 10 mg/kg/day) or saline for 4 days before receiving gavage with 10 (10) 14 C-labeled Escherichia coli and a 20% thermal injury. Mice were transfused with allogeneic blood and given dehydroepiandrosterone (5 or 25 mg/kg/day) or vehicle subcutaneously for 4 days before bacterial gavage and thermal injury. Some groups in each experiment were observed 10 days for mortality and others were sacrificed 4 hr postburn to measure translocation and survival of translocated bacteria. Survival in prednisone treated animals was 25% (10 mg/kg/day) and 75% (1 mg/kg/day) versus 80% for controls. Following dehydroepiandrosterone administration, survival was 72% (25 mg/kg/day/group) and 30% (5 mg/kg/day/group) versus 16% for controls. High dose prednisone increased bacterial translocation to the intestinal wall and mesenteric lymph nodes and greatly impaired killing of translocated E. coli. In contrast, dehydroepiandrosterone (25 mg/kg) did not affect translocation but significantly improved bacterial killing. Prednisone and dehydroepiandrosterone exert opposite effects during gut-derived sepsis.

Citing Articles

Decreasing the steroid rapidly may help to improve the clinical outcomes of patients with intestinal steroid-refractory acute graft-versus-host disease receiving basiliximab treatment.

Cheng C, Deng D, Zhang X, Xu L, Wang Y, Yan C Front Oncol. 2024; 14:1390438.

PMID: 38595816 PMC: 11002247. DOI: 10.3389/fonc.2024.1390438.


Safety, feasibility, and impact on the gut microbiome of kefir administration in critically ill adults.

Gupta V, Rajendraprasad S, Ozkan M, Ramachandran D, Ahmad S, Bakken J BMC Med. 2024; 22(1):80.

PMID: 38378568 PMC: 10880344. DOI: 10.1186/s12916-024-03299-x.


The human gut microbiome in critical illness: disruptions, consequences, and therapeutic frontiers.

Sung J, Rajendraprasad S, Philbrick K, Bauer B, Gajic O, Shah A J Crit Care. 2023; 79:154436.

PMID: 37769422 PMC: 11034825. DOI: 10.1016/j.jcrc.2023.154436.


Pharmacomicrobiomics of Classical Immunosuppressant Drugs: A Systematic Review.

Manes A, Di Renzo T, Dodani L, Reale A, Gautiero C, Di Lauro M Biomedicines. 2023; 11(9).

PMID: 37761003 PMC: 10526314. DOI: 10.3390/biomedicines11092562.


Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias.

Nikitin E, Kislova M, Morozov D, Belyakova V, Suvorova A, Sveshnikova J Leukemia. 2023; 37(7):1464-1473.

PMID: 37202442 PMC: 10195665. DOI: 10.1038/s41375-023-01891-3.